Oral DAV131, a charcoal-based adsorbent, inhibits intestinal colonization by β-lactam-resistant Klebsiella pneumoniae in cefotaxime-treated mice

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5423-5425

  Grall, Nathalie ^a,b   Massias, Laurent ^b   Nguyen, Thu Thuy ^c   Sayah Jeanne, Sakina ^d   Ducrot, Nicolas ^b   Chachaty, Elisabeth ^e   De Gunzburg, Jean ^d   Andremont, Antoine ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BICHAT HOSPITAL   (France)

^c INSERM   (France)

^d Da Volterra   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADSORBENT; ANTIBIOTIC AGENT; CEFOTAXIME; DAV131; ERTAPENEM; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; CONCENTRATION RESPONSE; DENSITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; FECES ANALYSIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE; KLEBSIELLA PNEUMONIAE INFECTION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADSORPTION; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BETA-LACTAM RESISTANCE; CEFOTAXIME; CHARCOAL; COLONY COUNT, MICROBIAL; DRUG SYNERGISM; FECES; FEMALE; INTESTINES; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE;

EID: 84885930176     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00039-13     Document Type: Article

References (16)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
2. Goossens H, Ferech M, Vander Stichele R, Elseviers M. 2005. Outpatient antibiotic use in Europe and association with resistance: a crossnational database study. Lancet 365:579-587.
3. Anonymous. 1948. Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. Br. Med. J. 2:769-782.
4. Tosh PK, McDonald LC. 2012. Infection control in the multidrugresistant era: tending the human microbiome. Clin. Infect. Dis. 54:707-713.
5. Servin AL. 2004. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol. Rev. 28:405-440.
6. O'Hara AM, Shanahan F. 2006. The gut flora as a forgotten organ. EMBO Rep. 7:688-693.
7. Vollaard EJ, Clasener HA. 1994. Colonization resistance. Antimicrob. Agents Chemother. 38:409-414.
8. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. 2001. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin. Infect. Dis. 32:1162-1171.
9. Donskey CJ. 2004. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin. Infect. Dis. 39:219-226.
10. Welling GW, Holtrop A, Slootmaker-van der Meulen C, Meijer-Severs GJ, van Santen E, Tonk RH, de Vries-Hospers HG, van der Waaij D. 1992. Inactivation of ceftriaxone by faecal enzyme preparations during ceftriaxone treatment. J. Antimicrob. Chemother. 30:234-236.
11. Pitout JD. 2009. IPSAT P1A, a class A beta-lactamase therapy for the prevention of penicillin-induced disruption to the intestinal microflora. Curr. Opin. Investig. Drugs 10:838-844.
12. Khoder M, Tsapis N, Huguet H, Besnard M, Gueutin C, Fattal E. 2009. Removal of ciprofloxacin in simulated digestive media by activated charcoal entrapped within zinc-pectinate beads. Int. J. Pharm. 379:251-259.
13. Khoder M, Tsapis N, Domergue-Dupont V, Gueutin C, Fattal E. 2010. Removal of residual colonic ciprofloxacin in the rat by activated charcoal entrapped within zinc-pectinate beads. Eur. J. Pharm. Sci. 41:281-288.
14. Nguyen TT, Chachaty E, Huy C, Cambier C, de Gunzburg J, Mentré F, Andremont A. 2012. Correlation between fecal concentrations of ciprofloxacin and fecal counts of resistant Enterobacteriaceae in piglets treated with ciprofloxacin: towards new means to control the spread of resistance? Antimicrob. Agents Chemother. 56:4973-4975.
15. Razazi K, Derde LP, Verachten M, Legrand P, Lesprit P, Brun-Buisson C. 2012. Clinical impact and risk factors for colonization with extendedspectrum β-lactamase-producing bacteria in the intensive care unit. Intensive Care Med. 38:1769-1778.
16. Grall N, Ducrot N, Massias L, Sayah-Jeanne S, Chachaty E, Nguyen T, De Gunzburg J, Andremont A. 2012. Orally administered DAV131, a formulated activated charcoal, inhibits establishment of intestinal colonization by beta-lactamine resistant Klebsiella pneumoniae in mice treated by cefotaxime, poster F-2003. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.